Literature DB >> 15712212

Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.

Sanjeev Shukla1, Gregory T Maclennan, Susan R Marengo, Martin I Resnick, Sanjay Gupta.   

Abstract

BACKGROUND: Cancer progression is usually facilitated by independent growth signals that may lead to increased cell survival and evasion of apoptosis. Phosphatidylinositol 3'-OH kinase (P I3 K)-Akt and transcription factor NF-kappaB are important signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis, and oncogenesis. Although P I3 K-Akt and NF-kappaB have been implicated in the development and progression of prostate cancer, expression of these molecules during progression of autochthonous disease has not been elucidated.
METHODS: Prostate cancer growth and progression in autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and male non-transgenic littermates were observed by magnetic resonance imaging (MRI). Expression patterns of P I3 K-Akt, NF-kappaB, I kappaB, and associated signaling molecules during different stages of cancer progression in these mice were examined by Western blot analysis, electrophoretic mobility shift assay (EMSA), enzyme-linked immunoabsorbent assay (ELISA), kinase assay, and immunohistochemistry.
RESULTS: Sequential MRI and gross analysis of prostate gland exhibited increasing prostate volume associated with the development and progression of prostatic adenocarcinoma in TRAMP mice, compared to male non-transgenic littermates. Differential protein expression of P I3 K, phosphorylated-Akt (Ser 473), I kappa Balpha and its phosphorylation, IKK kinase activity, NF-kappaB/p65, p50, DNA binding, and transcriptional-regulated genes, viz., Bc l2, cyclin D1, MMP-9, and VEGF were observed during prostate cancer progression in TRAMP mice, compared to male non-transgenic littermates. Expressions of these molecules were significantly increased during cancer progression observed at 24 and 32 weeks of age.
CONCLUSIONS: Differential expression pattern of P I3 K-Akt, NF-kappaB and I kappaB during prostate cancer progression in TRAMP mice suggest that these molecules represent potential molecular targets for prevention and/or therapeutic intervention. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712212     DOI: 10.1002/pros.20217

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  54 in total

Review 1.  RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.

Authors:  Aaron K Holley; Yong Xu; Daret K St Clair; William H St Clair
Journal:  Ann N Y Acad Sci       Date:  2010-07       Impact factor: 5.691

Review 2.  A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders.

Authors:  Keith D Coon; Travis L Dunckley; Dietrich A Stephan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  High-affinity interaction between IKKbeta and NEMO.

Authors:  Yu-Chih Lo; Upendra Maddineni; Jee Y Chung; Rebecca L Rich; David G Myszka; Hao Wu
Journal:  Biochemistry       Date:  2008-02-12       Impact factor: 3.162

4.  Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism.

Authors:  Matthew B Rettig; David Heber; Jiabin An; Navindra P Seeram; Jian Y Rao; Huiren Liu; Tobias Klatte; Arie Belldegrun; Aune Moro; Susanne M Henning; Deqiong Mo; William J Aronson; Allan Pantuck
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 5.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

6.  Linoleic acid induces migration and invasion through FFAR4- and PI3K-/Akt-dependent pathway in MDA-MB-231 breast cancer cells.

Authors:  Nathalia Serna-Marquez; Ricardo Diaz-Aragon; Emmanuel Reyes-Uribe; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  Med Oncol       Date:  2017-04-29       Impact factor: 3.064

7.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

8.  Vinclozolin exposure in utero induces postpubertal prostatitis and reduces sperm production via a reversible hormone-regulated mechanism.

Authors:  Prue A Cowin; Elspeth Gold; Jasna Aleksova; Moira K O'Bryan; Paul M D Foster; Hamish S Scott; Gail P Risbridger
Journal:  Endocrinology       Date:  2010-01-07       Impact factor: 4.736

Review 9.  The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target.

Authors:  Yonghui Yu; Yu Wan; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

10.  Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Authors:  Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.